Author:
Burghoff Julian,Ackermann Leonhard,Salahdine Younes,Bram Veronika,Wunderlich Katharina,Balkenhol Julius,Dirschka Thomas,Gottschalk Hanno
Publisher
Springer Nature Switzerland
Reference36 articles.
1. Gershenwald, J.E., Scolyer, R.A.: Melanoma staging: American joint committee on cancer (AJCC) and beyond. Ann. Surg. Oncol. 25(8), 2105–2110 (2018)
2. Landow, S.M., Gjelsvik, A., Weinstock, M.A.: Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, seer registry data, 1992–2013. J. Am. Acad. Dermatol. 76(2), 258–263 (2017)
3. Luke, J.J., et al.: Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (keynote-716): a randomised, double-blind, phase 3 trial. Lancet 399(10336), 1718–1729 (2022)
4. Bristol myers squibb announces adjuvant treatment with opdivo (nivolumab) demonstrated statistically significant and clinically meaningful improvement in recurrence-free survival (rfs) in patients with stage iib/c melanoma in the checkmate -76k trial. https://bit.ly/3dfAO8B. Accessed 16 Sep 2022
5. Rizk, E.M., et al.: Biomarkers predictive of survival and response to immune checkpoint inhibitors in melanoma. Am. J. Clin. Dermatol. 21(1), 1–11 (2020)